FOSTER CITY, CA--(MARKET WIRE)--Oct 27, 2008 -- SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN - News) today announced that it will report results for the third quarter ended September 30, 2008 and host a conference call on Thursday, November 6, 2008.

Management will review operating results for the third quarter 2008 and give a business update. The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com.

 
DATE:           Thursday, November 6, 2008
TIME:           11:00 a.m. ET (8:00 a.m. PT)
WEBCAST:        Live call and replay accessible at http://www.sciclone.com
LIVE CALL:      800-211-3767  (U.S./Canada)
                719-955-1564  (International)
REPLAY:         888-203-1112  (U.S./Canada)
                719-457-0820  (International)
                Passcode:  8199423
                (Replay available from Thursday, November 6, 2008 at
                2:00 p.m. ET until 11:59 p.m. ET on Wednesday,
                December 3, 2008)

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in a late-stage clinical trial for the treatment of hepatitis C, and successfully completed a phase 2 clinical trial in malignant melanoma. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC BeadTM. SciClone's other clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C. For more information about SciClone, visit www.sciclone.com.

     Corporate Contact
     Ana Kapor
     SciClone Pharmaceuticals, Inc.
     650-358-3437
     Email Contact